{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:44:46Z","timestamp":1782398686856,"version":"3.54.5"},"reference-count":31,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Epinephrine is the first-line treatment for anaphylaxis, a potentially life-threatening allergic reaction. Despite this, real-world epinephrine use remains suboptimal.\n                    <jats:bold>Objective:<\/jats:bold>\n                    In this survey study of patients and caregivers of patients with\n anaphylaxis, the objective was to characterize real-world use of over-the-counter (OTC) medications alone or before epinephrine and to evaluate factors inherent to epinephrine delivery devices in contributing to delayed epinephrine use.\n                    <jats:bold>Methods:<\/jats:bold>\n                    Participants included U.S.\n patients (n = 100) and caregivers of patients with immunoglobulin E (IgE) mediated allergy (n = 100) who used an epinephrine autoinjector (EAI) in the past 12 months. A double-blind online survey evaluated allergy history, management of severe allergic reactions, and reasons for delaying epinephrine\n use.\n                    <jats:bold>Results:<\/jats:bold>\n                    Most respondents reported using OTC medications alone (88%) or before using an EAI (89%) to manage allergic reactions. During their most recent reactions, 42% of the respondents delayed or hesitated to use an EAI, with an average of 8.8 minutes before administration.\n The most impactful factor that contributes to delayed EAI use was concern about the device needle. Respondents who reported using OTC medications to manage most allergic reactions estimated that they would use needle-free epinephrine over OTC medications approximately three-fourths of the\n time.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Despite potential risks of delaying using epinephrine, OTC medications are commonly used alone or before epinephrine use. Given the concerns about device needles identified in this survey, needle-free epinephrine offers an alternative to EAIs.\n                  <\/jats:p>","DOI":"10.2500\/aap.2026.47.250082","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:32:26Z","timestamp":1768019546000},"page":"40-46","source":"Crossref","is-referenced-by-count":1,"title":["Incorrect perceptions of first-line treatment of severe allergic reactions with over-the-counter products and how the epinephrine drug delivery system impacts behavior"],"prefix":"10.2500","volume":"47","author":[{"given":"Raffi","family":"Tachdjian","sequence":"first","affiliation":[{"name":"From the David Geffen School of Medicine, University of California, Los Angeles, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Chase","sequence":"additional","affiliation":[{"name":"University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn","family":"Burnette","sequence":"additional","affiliation":[{"name":"Howard University Hospital, Washington, D.C.;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kaufman","sequence":"additional","affiliation":[{"name":"LSU Health Shreveport, Shreveport, Louisiana; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"ARS Pharmaceuticals Operations, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Kafal","sequence":"additional","affiliation":[{"name":"ARS Pharmaceuticals Operations, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2017.06.031","article-title":"Fatal anaphylaxis: mortality rate and risk factors","volume":"5","author":"Turner","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/all.14683","article-title":"Peanut-induced anaphylaxis in children and adolescents: data from the European Anaphylaxis Registry","volume":"76","author":"Maris","year":"2021","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/all.12924","article-title":"Can we identify patients at risk of life-threatening allergic reactions to food?","volume":"71","author":"Turner","year":"2016","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2019.12.015","article-title":"Epinephrine in the management of anaphylaxis","volume":"8","author":"Brown","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/all.15032","article-title":"EAACI guidelines: anaphylaxis (2021 update)","volume":"77","author":"Muraro","year":"2022","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World Allergy Organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B9","doi-asserted-by":"crossref","first-page":"e20164006","DOI":"10.1542\/peds.2016-4006","article-title":"Epinephrine for first-aid management of anaphylaxis","volume":"139","author":"Sicherer","year":"2017","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.jaip.2018.02.026","article-title":"Epinephrine in severe allergic reactions: the European Anaphylaxis Register","volume":"6","author":"Grabenhenrich","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaip.2014.07.004","article-title":"Early treatment of food-induced anaphylaxis with epinephrine is associated with a lower risk of hospitalization","volume":"3","author":"Fleming","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.anai.2023.08.606","article-title":"Managing anaphylaxis: epinephrine, antihistamines, and corticosteroids: more than 10 years of Cross-Canada Anaphylaxis REgistry data","volume":"131","author":"Delli Colli","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.anai.2024.08.006","article-title":"Outcomes associated with prehospital epinephrine in adult and pediatric patients with anaphylaxis","volume":"133","author":"Hlady","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1097\/PEC.0000000000002146","article-title":"Outcomes and factors associated with prehospital treatment of pediatric anaphylaxis","volume":"38","author":"Trainor","year":"2022","journal-title":"Pediatr Emerg Care"},{"key":"B15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.anai.2020.09.012","article-title":"Factors contributing to underuse of epinephrine autoinjectors in pediatric patients with food allergy","volume":"126","author":"Glassberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B16","article-title":"My life with food allergy parent survey report","year":"2019"},{"key":"B17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2222.2011.03912.x","article-title":"The use of adrenaline autoinjectors by children and teenagers","volume":"42","author":"Noimark","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"B18","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.jaip.2019.04.018","article-title":"Evaluation of prehospital management in a Canadian emergency department anaphylaxis cohort","volume":"7","author":"Gabrielli","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jaci.2013.10.029","article-title":"Case fatality and population mortality associated with anaphylaxis in the United States","volume":"133","author":"Ma","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J Adv Nurs"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/all.12262","article-title":"A majority of parents of children with peanut allergy fear using the epinephrine auto-injector","volume":"68","author":"Chad","year":"2013","journal-title":"Allergy"},{"key":"B22","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jaci.2023.08.007","article-title":"Pharmacokinetics\/pharmacodynamics of epinephrine after single and repeat administration of neffy, EpiPen, and manual intramuscular injection","volume":"152","author":"Casale","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3390\/pharmaceutics16060811","article-title":"Development of neffy, an epinephrine nasal spray, for severe allergic reactions","volume":"16","author":"Ellis","year":"2024","journal-title":"Pharmaceutics"},{"key":"B24","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaip.2023.11.006","article-title":"Adult pharmacokinetics of self-administration of epinephrine nasal spray 2.0 mg versus manual intramuscular epinephrine 0.3 mg by health care provider","volume":"12","author":"Casale","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jaip.2024.02.038","article-title":"Upper respiratory tract infections have minimal impact on neffy's pharmacokinetics or pharmacodynamics","volume":"12","author":"Oppenheimer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.anai.2022.10.024","article-title":"Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly: an integrated analysis","volume":"130","author":"Tanimoto","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"100200","DOI":"10.1016\/j.jacig.2023.100200","article-title":"A 13.2 mg epinephrine intranasal spray demonstrates comparable pharmacokinetics, pharmacodynamics, and safety to a 0.3 mg epinephrine autoinjector","volume":"3","author":"Dworaczyk","year":"2023","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B28","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1016\/j.jaip.2023.06.044","article-title":"Fast acting, dry powder, needle-free, intranasal epinephrine spray: a promising future treatment for anaphylaxis","volume":"11","author":"Tal","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"crossref","first-page":"AB6","DOI":"10.1016\/j.jaci.2022.12.023","article-title":"Pharmacokinetics of epinephrine sublingual film following three different administration procedures","volume":"151","author":"Bernstein","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ajem.2020.10.060","article-title":"Patient\/parent administered epinephrine in acute anaphylaxis","volume":"46","author":"Murata","year":"2021","journal-title":"Am J Emerg Med"},{"key":"B31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.anai.2018.06.010","article-title":"Epinephrine auto-injector carriage and use practices among US children, adolescents, and adults","volume":"121","author":"Warren","year":"2018","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000001\/art00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:33:26Z","timestamp":1768019606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.250082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["1088-5412(20260101)47:1L.40;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.250082","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}